• Something wrong with this record ?

Effects of nebivolol on biomarkers in elderly patients with heart failure

AK. Taneja, D. Gaze, AJ. Coats, D. Dumitrascu, L. Spinarova, P. Collinson, M. Roughton, MD. Flather, . ,

. 2014 ; 175 (2) : 253-60.

Language English Country Netherlands

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15023368

BACKGROUND: Heart failure activates neurohormones, and elevated levels of brain natriuretic peptide (BNP) are associated with adverse outcomes. The SENIORS trial showed that nebivolol, a highly selective beta-1 antagonist with vasodilating properties, reduced the composite outcome of all cause mortality or cardiovascular hospital admissions in older patients with heart failure. We explored the effects of nebivolol on a range of neurohormones, cytokines and markers of nitric oxide activity in heart failure. METHODS: In a subset of patients in SENIORS we measured N-terminal pro-brain natriuretic peptide (NT-BNP), pro atrial natriuretic peptide (Pro-ANP), endothelin-1 (ET-1), peripheral norepinephrine (PNE), soluble Fas (sFas), soluble Fas-ligand (sFas-L), tumour necrosis factor-alpha (TNF-α), serum uric acid (SUA), symmetrical dimethyl arginine (SDMA), arginine, citrulline and asymmetrical dimethyl arginine (ADMA) at baseline (before study drug), at 6 months and 12 months in a prespecified substudy. RESULTS: One hundred and six patients were enrolled and 75 had a baseline and at least one follow-up sample. There were no significant differences in neurohormone cytokines or nitric oxide markers measured between the two groups at six or twelve months. NT-ProBNP showed a numerical increase in the nebivolol group compared to placebo (P=0.08) and sFas showed a numerical increase in patients on placebo (P=0.08). Mean baseline LVEF was 35% in both groups and at 12 months was 43% on nebivolol group and 34% on placebo group (P=0.01). CONCLUSION: There were trends but no clear changes associated with nebivolol in neurohormones, cytokines or markers of nitric oxide activity in this study of elderly patients with heart failure. Further studies are needed to understand the mechanistic effects of beta blockers on biomarkers in heart failure.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023368
003      
CZ-PrNML
005      
20150729113516.0
007      
ta
008      
150709s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcard.2014.05.018 $2 doi
035    __
$a (PubMed)24877590
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Taneja, Anil K $u Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. Electronic address: aniltaneja00@hotmail.com.
245    10
$a Effects of nebivolol on biomarkers in elderly patients with heart failure / $c AK. Taneja, D. Gaze, AJ. Coats, D. Dumitrascu, L. Spinarova, P. Collinson, M. Roughton, MD. Flather, . ,
520    9_
$a BACKGROUND: Heart failure activates neurohormones, and elevated levels of brain natriuretic peptide (BNP) are associated with adverse outcomes. The SENIORS trial showed that nebivolol, a highly selective beta-1 antagonist with vasodilating properties, reduced the composite outcome of all cause mortality or cardiovascular hospital admissions in older patients with heart failure. We explored the effects of nebivolol on a range of neurohormones, cytokines and markers of nitric oxide activity in heart failure. METHODS: In a subset of patients in SENIORS we measured N-terminal pro-brain natriuretic peptide (NT-BNP), pro atrial natriuretic peptide (Pro-ANP), endothelin-1 (ET-1), peripheral norepinephrine (PNE), soluble Fas (sFas), soluble Fas-ligand (sFas-L), tumour necrosis factor-alpha (TNF-α), serum uric acid (SUA), symmetrical dimethyl arginine (SDMA), arginine, citrulline and asymmetrical dimethyl arginine (ADMA) at baseline (before study drug), at 6 months and 12 months in a prespecified substudy. RESULTS: One hundred and six patients were enrolled and 75 had a baseline and at least one follow-up sample. There were no significant differences in neurohormone cytokines or nitric oxide markers measured between the two groups at six or twelve months. NT-ProBNP showed a numerical increase in the nebivolol group compared to placebo (P=0.08) and sFas showed a numerical increase in patients on placebo (P=0.08). Mean baseline LVEF was 35% in both groups and at 12 months was 43% on nebivolol group and 34% on placebo group (P=0.01). CONCLUSION: There were trends but no clear changes associated with nebivolol in neurohormones, cytokines or markers of nitric oxide activity in this study of elderly patients with heart failure. Further studies are needed to understand the mechanistic effects of beta blockers on biomarkers in heart failure.
650    _2
$a antagonisté beta-1-adrenergních receptorů $x terapeutické užití $7 D058671
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a benzopyrany $x terapeutické užití $7 D001578
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a cytokiny $x krev $7 D016207
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ethanolaminy $x terapeutické užití $7 D004983
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x krev $x farmakoterapie $7 D006333
650    _2
$a lidé $7 D006801
650    12
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neurotransmiterové látky $x krev $7 D018377
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gaze, David $u Department of Chemical Pathology, St. George's Hospital, London, UK.
700    1_
$a Coats, Andrew J S $u Monash University, Australia; Melbourne University, Australia; Warwick University, UK.
700    1_
$a Dumitrascu, Dan $u Cluj-Napoca University Hospital, Romania.
700    1_
$a Spinarova, Lenka $u 1st Internal Cardioangiological Dept, St. Anne's Hospital & Medical Faculty, Brno, Czech Republic.
700    1_
$a Collinson, Paul $u Cardiovascular Markers, St. George's Hospital University, London, UK.
700    1_
$a Roughton, Michael $u Novartis, Basel, Switzerland.
700    1_
$a Flather, Marcus D $u Norwich Medical School, University of East Anglia, UK; Previously Royal Brompton and Harefield NHS Foundation Trust/Imperial College, London, UK.
700    1_
$a ,
773    0_
$w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 175, č. 2 (2014), s. 253-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24877590 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729113602 $b ABA008
999    __
$a ok $b bmc $g 1083705 $s 906361
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 175 $c 2 $d 253-60 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Archiving options